Oslo ,18 January 2021 : Reference is made toNavamedic ASA's ("Navamedic " or the "Company") stock exchange announcement published on4 January 2021 regarding the board of director's resolution to increase the Company's share capital in connection with the settlement of tranche 1 of the purchase price by issuing consideration shares for the acquisition of marketing authorisations for a series of antibiotics for hospital use in the Nordic region fromACS Dobfar andInfoRLife . The share capital increase pertaining to the 1,053,775 consideration shares has now been registered with theNorwegian Register ofBusiness Enterprises (Nw. Foretaksregisteret). The new share capital of the Company is 12,095,788.40, divided into 16,345,660 shares, each with a par value ofNOK 0.74 . Following the registration of the new shares in theNorwegian Central Securities Depository (the VPS), which is expected to take place today, the new shares will be delivered to the subscriber and listed on theOslo Stock Exchange . For further information, please contact:Kathrine Gamborg Andreassen , CEO,Navamedic Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand, CFO,Navamedic Mobile: +47 917 62 842 E-mail: lars.hjarrand@navamedic.com AboutNavamedic Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies.Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge.Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in theUK andGreece .Navamedic is headquartered inOslo, Norway , and listed on theOslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com This information is subject to the disclosure requirements pursuant to the issuer rules for Oslo Børs.
Click here for more information
© Oslo Bors ASA, source